Haemophilia prophylactic treatment in Spain

被引：4
|
作者：
Tusell, J [1 ]
Cid, AR [1 ]
Sosa, R [1 ]
Villar, A [1 ]
Lucia, JF [1 ]
机构：
[1] Hosp Valle De Hebron, Barcelona 08035, Spain
来源：
HAEMOPHILIA | 2002年 / 8卷 / 05期
关键词：
D O I：
10.1046/j.1365-2516.2002.00657.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：729 / 730
页数：2
相关论文
共 50 条
  • [31] Prophylactic treatment with recombinant activated factor VII in paediatric patients with haemophilia A and inhibitors
    Cermelj, M. A.
    Ferro, A. M.
    Ouvina, S. M.
    Pollola, J. A.
    Paoloski, G. B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 694 - 695
  • [32] Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment
    Andersson, Nadine G.
    Auerswald, Guenter
    Barnes, Chris
    Carcao, Manuel
    Dunn, Amy L.
    Fijnvandraat, Karin
    Hoffmann, Marianne
    Kavakli, Kaan
    Kenet, Gili
    Kobelt, Rainer
    Kurnik, Karin
    Liesner, Ri
    Makipernaa, Anne
    Manco-Johnson, Marilyn J.
    Mancuso, Maria E.
    Molinari, Angelo C.
    Nolan, Beatrice
    Perez Garrido, Rosario
    Petrini, Pia
    Platokouki, Helen E.
    Shapiro, Amy D.
    Wu, Runhui
    Ljung, Rolf
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (02) : 298 - 307
  • [33] Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?
    Siegmund, B
    Richter, H
    Pollmann, H
    HAEMOPHILIA, 2005, 11 (06) : 638 - 641
  • [34] Prophylactic Treatment of Severe Haemophilia a Patients with Inhibitors to FVIII with Peglip-FVIII
    Tuddenham, Edward
    Wolf-Garraway, Richard
    Ling, Gavin
    BLOOD, 2022, 140 : 5617 - 5618
  • [35] Quality of life assessment and pharmacokinetic study in haemophilia A patients undergoing prophylactic treatment
    Kotsiou, N.
    Gavriilaki, E.
    Chissan, S.
    Ntova, Z.
    Moka, E.
    Aivazidou, S.
    Katsetsiadis, A.
    Kalmoukos, P.
    Vakalopoulou, S.
    HAEMOPHILIA, 2024, 30 : 109 - 110
  • [36] Prophylactic therapy for haemophilia: early experience
    Berntorp, E
    HAEMOPHILIA, 2003, 9 : 5 - 9
  • [37] Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain
    Batlle, Javier
    Villar, Ana
    Liras, Antonio
    Alonso, Concepcion
    Altisent, Carmen
    Brito, Dilia
    Moreno, Manuel
    Lucia, Felix
    Sedano, Carmen
    Prieto, Manuel
    Calvente, Natividad
    Aznar, Jose A.
    Jimenez, Victor
    Soriano, Vicente
    Martorell, Javier R.
    Iruin, Gemma
    Bergua, Juan M.
    Aguilar, Carlos
    BLOOD COAGULATION & FIBRINOLYSIS, 2008, 19 (05) : 333 - 340
  • [38] Cost-effectiveness of regular continuous prophylactic treatment in adult patients with severe haemophilia A
    Monzini, M
    Gringeri, A
    Ravera, S
    Mantovani, LG
    VALUE IN HEALTH, 2005, 8 (06) : A125 - A126
  • [39] Barriers to prophylactic treatment among patients with haemophilia A in Shandong Province, China: a qualitative study
    Ziyu Liu
    Junchao Feng
    Yunhai Fang
    Yan Cheng
    Shunping Li
    Orphanet Journal of Rare Diseases, 18
  • [40] Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A
    Carlsson, M
    Berntorp, E
    Bjorkman, S
    Lethagen, S
    Ljung, R
    HAEMOPHILIA, 1997, 3 (02) : 96 - 101
12345